These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 33693561)

  • 1. Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus.
    Marconi VC; Moser C; Gavegnano C; Deeks SG; Lederman MM; Overton ET; Tsibris A; Hunt PW; Kantor A; Sekaly RP; Tressler R; Flexner C; Hurwitz SJ; Moisi D; Clagett B; Hardin WR; Del Rio C; Schinazi RF; Lennox JJ
    Clin Infect Dis; 2022 Jan; 74(1):95-104. PubMed ID: 33693561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agent Therapy from the ACTG A5336 Study.
    Hurwitz SJ; Tao S; Gavegnano C; Jiang Y; Tressler RL; Tsibris A; Del Rio C; Overton ET; Lederman MM; Kantor A; Moser C; Kohler JJ; Lennox J; Marconi VC; Flexner CW; Schinazi RF
    J Clin Pharmacol; 2021 Dec; 61(12):1555-1566. PubMed ID: 34169526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
    Vogler MA; Teppler H; Gelman R; Valentine F; Lederman MM; Pomerantz RJ; Pollard RB; Cherng DW; Gonzalez CJ; Squires KE; Frank I; Mildvan D; Mahon LF; Schock B;
    J Acquir Immune Defic Syndr; 2004 May; 36(1):576-87. PubMed ID: 15097300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy.
    Yi TJ; Walmsley S; Szadkowski L; Raboud J; Rajwans N; Shannon B; Kumar S; Kain KC; Kaul R; Tan DH
    Clin Infect Dis; 2013 Nov; 57(9):1331-8. PubMed ID: 23946220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection.
    Dubé MP; Chan ES; Lake JE; Williams B; Kinslow J; Landay A; Coombs RW; Floris-Moore M; Ribaudo HJ; Yarasheski KE
    Clin Infect Dis; 2019 Sep; 69(7):1165-1172. PubMed ID: 30535188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
    Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
    JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy.
    Funderburg NT; Jiang Y; Debanne SM; Storer N; Labbato D; Clagett B; Robinson J; Lederman MM; McComsey GA
    Clin Infect Dis; 2014 Feb; 58(4):588-95. PubMed ID: 24253250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
    Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
    Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Antiretroviral Therapy on Immune Function and Arterial Inflammation in Treatment-Naive Patients With Human Immunodeficiency Virus Infection.
    Zanni MV; Toribio M; Robbins GK; Burdo TH; Lu MT; Ishai AE; Feldpausch MN; Martin A; Melbourne K; Triant VA; Suchindran S; Lee H; Hoffmann U; Williams KC; Tawakol A; Grinspoon SK
    JAMA Cardiol; 2016 Jul; 1(4):474-80. PubMed ID: 27438325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
    Kelesidis T; Tran TT; Stein JH; Brown TT; Moser C; Ribaudo HJ; Dube MP; Murphy R; Yang OO; Currier JS; McComsey GA
    Clin Infect Dis; 2015 Aug; 61(4):651-60. PubMed ID: 25904376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. During Stably Suppressive Antiretroviral Therapy Integrated HIV-1 DNA Load in Peripheral Blood is Associated with the Frequency of CD8 Cells Expressing HLA-DR/DP/DQ.
    Ruggiero A; De Spiegelaere W; Cozzi-Lepri A; Kiselinova M; Pollakis G; Beloukas A; Vandekerckhove L; Strain M; Richman D; Phillips A; Geretti AM;
    EBioMedicine; 2015 Sep; 2(9):1153-9. PubMed ID: 26498496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High residual inflammation despite HIV viral suppression: Lessons learned from real-time adherence monitoring among people with HIV in Africa.
    Castillo-Mancilla JR; Musinguzi N; Asiimwe S; Siedner MJ; Orrell C; Bangsberg DR; Haberer JE
    HIV Med; 2022 May; 23(5):465-473. PubMed ID: 34704355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study.
    Passamonti F; Palandri F; Saydam G; Callum J; Devos T; Guglielmelli P; Vannucchi AM; Zor E; Zuurman M; Gilotti G; Zhang Y; Griesshammer M
    Lancet Haematol; 2022 Jul; 9(7):e480-e492. PubMed ID: 35597252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.
    Rosmarin D; Passeron T; Pandya AG; Grimes P; Harris JE; Desai SR; Lebwohl M; Ruer-Mulard M; Seneschal J; Wolkerstorfer A; Kornacki D; Sun K; Butler K; Ezzedine K;
    N Engl J Med; 2022 Oct; 387(16):1445-1455. PubMed ID: 36260792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repurposing BCL-2 and Jak 1/2 inhibitors: Cure and treatment of HIV-1 and other viral infections.
    Reece MD; Song C; Hancock SC; Pereira Ribeiro S; Kulpa DA; Gavegnano C
    Front Immunol; 2022; 13():1033672. PubMed ID: 36569952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy.
    O'Brien MP; Hunt PW; Kitch DW; Klingman K; Stein JH; Funderburg NT; Berger JS; Tebas P; Clagett B; Moisi D; Utay NS; Aweeka F; Aberg JA
    Open Forum Infect Dis; 2017; 4(1):ofw278. PubMed ID: 28480270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin 6 Blockade With Tocilizumab Diminishes Indices of Inflammation That Are Linked to Mortality in Treated Human Immunodeficiency Virus Infection.
    Funderburg NT; Shive CL; Chen Z; Tatsuoka C; Bowman ER; Longenecker CT; McComsey GA; Clagett BM; Dorazio D; Freeman ML; Sieg SF; Moisi D; Anthony DD; Jacobson JM; Stein SL; Calabrese LH; Landay A; Flexner C; Crawford KW; Capparelli EV; Rodriguez B; Lederman MM
    Clin Infect Dis; 2023 Jul; 77(2):272-279. PubMed ID: 37011013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers.
    Li JZ; Segal FP; Bosch RJ; Lalama CM; Roberts-Toler C; Delagreverie H; Getz R; Garcia-Broncano P; Kinslow J; Tressler R; Van Dam CN; Keefer M; Carrington M; Lichterfeld M; Kuritzkes D; Yu XG; Landay A; Sax PE;
    Clin Infect Dis; 2020 Apr; 70(8):1636-1642. PubMed ID: 31131858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine/tenofovir disoproxil fumarate for medication of treatment-naïve HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96.
    Su B; Gao G; Wang M; Lu Y; Li L; Chen C; Chen Y; Song C; Yu F; Li Y; Liu Y; Luo Y; He H; Cheng C; Xu L; Zhang T; Sun L; Liu A; Xia W; Qin Y; Zhao Q; Wei H; Cai W; Chen Y; Zhang F; Wu H
    Lancet Reg Health West Pac; 2023 Jul; 36():100769. PubMed ID: 37547039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.